GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    SAGE Publications ; 1982
    In:  Drug Intelligence & Clinical Pharmacy Vol. 16, No. 5 ( 1982-05), p. 398-399
    In: Drug Intelligence & Clinical Pharmacy, SAGE Publications, Vol. 16, No. 5 ( 1982-05), p. 398-399
    Type of Medium: Online Resource
    ISSN: 0012-6578
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1982
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    SAGE Publications ; 1989
    In:  DICP Vol. 23, No. 10 ( 1989-10), p. 757-763
    In: DICP, SAGE Publications, Vol. 23, No. 10 ( 1989-10), p. 757-763
    Abstract: This article reviews amiodarone's adverse cardiovascular properties, concentrating on those in surgical patients, and evaluates several potential risk factors. Amiodarone has negative inotropic and chronotropic properties as well as peripheral vasodilating properties that may manifest as bradycardia, reduced cardiac output, and hypotension. These reactions are clinically important during surgery, because of resistance to pharmacologic resuscitation and an increased mortality rate. Potential risk factors include ventricular dysfunction, rapid infusion rate, hypocalcemia, cardiopulmonary bypass, general anesthesia, concurrent negative inotropic or chronotropic drugs, and an elevated serum amiodarone or desethylamiodarone concentration. The following measures may decrease the risk of intraoperative adverse reactions in amiodarone-treated patients. The serum calcium concentration should be at the physiologic level and the serum amiodarone and digoxin concentrations should be in the therapeutic range. Negative inotropic and chronotropic agents should be discontinued when possible. A temporary cardiac pacemaker may prevent intraoperative hypotension due to bradycardia. Amiodarone may be discontinued before surgery to minimize the risk of intraoperative complications, but this decision should balance the potential for amiodarone-associated intraoperative complications against the risk of arrhythmia recurrence and the delay of surgery.
    Type of Medium: Online Resource
    ISSN: 1042-9611
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1989
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    SAGE Publications ; 1993
    In:  Annals of Pharmacotherapy Vol. 27, No. 3 ( 1993-03), p. 351-357
    In: Annals of Pharmacotherapy, SAGE Publications, Vol. 27, No. 3 ( 1993-03), p. 351-357
    Abstract: Factors affecting aminoglycoside dosing requirements in critically ill adult patients were reviewed. DATA SOURCES: A literature search was performed from 1979 to 1992 and articles pertaining to aminoglycoside dosing were obtained. STUDY SELECTION: Only studies appearing in peer-reviewed journals were selected. Topics selected included: Bactericidal kill kinetics, once-daily dosing regimens, critical illness, toxicity, aminoglycosides, intensive care unit, and lung penetration. CONCLUSIONS: Studies suggest that larger initial aminoglycoside doses are necessary in critically ill patients (tobramycin/gentamicin 3 mg/kg or amikacin 9 mg/kg) to achieve adequate peak serum concentrations. Current studies have not shown an increase in the incidence of aminoglycoside toxicity when using these larger initial doses. Follow-up monitoring is dependent upon the patient's physiology and risk factors for aminoglycoside-induced toxicity.
    Type of Medium: Online Resource
    ISSN: 1060-0280 , 1542-6270
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1993
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    SAGE Publications ; 2010
    In:  Annals of Pharmacotherapy Vol. 44, No. 4 ( 2010-04), p. 688-700
    In: Annals of Pharmacotherapy, SAGE Publications, Vol. 44, No. 4 ( 2010-04), p. 688-700
    Abstract: To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. Data sources Articles were identified via a search of the MEDLINE database, including publications from 1979 to December 2009, using a search string that included the terms parenteral nutrition, lipid emulsion, fat emulsion, IVFE, safety, adverse effect, neonate intralipid, and terms describing a range of specific adverse events (AEs) such as pancreatitis. Study selection and data extraction We selected articles that allowed us to compare the results of clinical trials involving delivery of medications via IVFEs with the historical use and effects of IVFEs in parenteral nutrition, with an emphasis on AEs. We focused on 2 drugs in current use that are administered intravenously in lipid emulsions: propofol and clevidipine. Data synthesis Clearance of the fat particles in IVFEs is mediated by the enzyme lipoprotein lipase. AEs are more likely if the rate or duration of IVFE administration exceeds the enzyme's clearance capacity. AEs are also more likely after administration of a 10% IVFE formulation than a 20% formulation, because the higher concentration of free phospholipid in the 10% formulation interferes with lipoprotein lipase activity. AEs can be reduced by administering IVFEs at a dosage ≤2.5 g/kg/day and at a rate ≤0.11 g/kg/h. The anesthetic agent propofol, which is formulated in a 10% IVFE, has been used clinically for 25 years. Typical AEs associated with propofol use include infection, high plasma triglyceride concentrations, and pancreatitis. Recent clinical trials involving clevidipine, which is formulated in a 20% IVFE, have demonstrated a low rate of lipid-related AEs. Conclusions The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.
    Type of Medium: Online Resource
    ISSN: 1060-0280 , 1542-6270
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2010
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    SAGE Publications ; 2011
    In:  Annals of Pharmacotherapy Vol. 45, No. 3 ( 2011-03), p. 380-387
    In: Annals of Pharmacotherapy, SAGE Publications, Vol. 45, No. 3 ( 2011-03), p. 380-387
    Abstract: To compare the pharmacology, dosing, and adverse reactions of vasopressin and terlipressin for the treatment of hepatorenal syndrome (HRS) and assess the efficacy of the investigational drug terlipressin for HRS. Data Sources: Articles evaluating prospective studies for vasopressin and terlipressin were discussed after being identified through PubMed (1966-November 2010), International Pharmaceutical Abstracts (1970-November 2010), and EMBASE (1985-November 2010) with combinations of the following terms: vasopressin, terlipressin, and hepatorenal syndrome. In addition, reference citations from publications identified were reviewed. Thirteen studies were identified for terlipressin, along with 4 meta-analyses and 1 case report. For vasopressin, 2 studies were identified. Study Selection and Data Extraction: Prospective clinical studies directly comparing terlipressin and vasopressin were evaluated, as well as prospective clinical studies and meta-analyses for terlipressin in HRS. Data Synthesis: NO randomized, placebo-controlled trials using vasopressin for the treatment of type I HRS have been published, and 4 randomized studies Involving 197 patients provide the most current outcome data for use of terlipressin in HRS. Terlipressin differs significantly from vasopressin with regard to its pharmacology, dosing, and adverse drug reaction profile. There is a paucity of data on vasopressin for HRS. Conclusions: NO definitive recommendations can be made for the use of terlipressin for this indication until further, well-conducted studies are performed.
    Type of Medium: Online Resource
    ISSN: 1060-0280 , 1542-6270
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2011
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    SAGE Publications ; 1984
    In:  Drug Intelligence & Clinical Pharmacy Vol. 18, No. 12 ( 1984-12), p. 965-970
    In: Drug Intelligence & Clinical Pharmacy, SAGE Publications, Vol. 18, No. 12 ( 1984-12), p. 965-970
    Type of Medium: Online Resource
    ISSN: 0012-6578
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1984
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    SAGE Publications ; 1994
    In:  Annals of Pharmacotherapy Vol. 28, No. 7-8 ( 1994-07), p. 915-924
    In: Annals of Pharmacotherapy, SAGE Publications, Vol. 28, No. 7-8 ( 1994-07), p. 915-924
    Abstract: To review published reports of adverse effects associated with single- and multiple-dose activated charcoal therapy, and to formulate recommendations for safe use of activated charcoal therapy. DATA SOURCES: A manual search of Index Medicus from 1970 to December 1993 was conducted for English language articles; bibliographies of the resultant articles were also scanned. STUDY SELECTION: Cases were included if they were described in full detail, resulted in significant morbidity or mortality, and uniquely contributed to the formulation of recommendations for safe use of activated charcoal therapy. DATA SYNTHESIS: The major causes of morbidity and mortality secondary to activated charcoal therapy are aspiration of charcoal, gastrointestinal obstruction, and fluid and electrolyte abnormalities. Aspirations have occurred as a result of a number of circumstances that may be avoided. These include use in patients with unprotected airways, use of excessive charcoal dose, administration of inappropriately diluted charcoal, and administration of charcoal in the field. Gastrointestinal obstruction has occurred when multiple doses of activated charcoal have been administered without a cathartic and in cases in which a cathartic was administered if the patient had impaired peristalsis. Fluid and electrolyte abnormalities have occurred secondary to excessive cathartic administration. CONCLUSIONS: Activated charcoal therapy should be used judiciously so that related morbidity and mortality can be prevented. Adequate consideration for the patient's airway protection capability is necessary. Judicious dosing of charcoal and concomitant cathartic therapy, along with adequate monitoring of fluid and electrolyte status, abdominal physical assessment, and clinical condition are all vital to the safe use of activated charcoal therapy.
    Type of Medium: Online Resource
    ISSN: 1060-0280 , 1542-6270
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1994
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    SAGE Publications ; 1992
    In:  Annals of Pharmacotherapy Vol. 26, No. 6 ( 1992-06), p. 843-843
    In: Annals of Pharmacotherapy, SAGE Publications, Vol. 26, No. 6 ( 1992-06), p. 843-843
    Type of Medium: Online Resource
    ISSN: 1060-0280 , 1542-6270
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1992
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: DICP, SAGE Publications, Vol. 25, No. 3 ( 1991-03), p. 276-283
    Abstract: Parenteral nutrient (PN) admixtures are the most complex, extemporaneously compounded formulations routinely prepared for hospitalized and home-based patients. In addition, drugs are added with increasing frequency to PN admixtures, thus presenting even greater physicochemical challenges to this highly complex pharmaceutical product. The continuous infusion of selected drugs may provide pharmacokinetic and therapeutic advantages over conventional, intermittent, bolus methods of administration. Fluid conservation, cost savings, and a possible decrease in the risk of infection through reduced catheter manipulation and simplification of therapy provide additional incentives to consider the use of PN admixtures. The many advantages of PN admixtures make them an attractive approach to cost-effective care, with special clinical benefits achieved in the critical care setting. This article reviews our clinical experience using PN admixtures as drug vehicles for selected drugs and presents some theoretical as well as actual benefits associated with this practice.
    Type of Medium: Online Resource
    ISSN: 1042-9611
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1991
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    SAGE Publications ; 1990
    In:  DICP Vol. 24, No. 12 ( 1990-12), p. 1195-1203
    In: DICP, SAGE Publications, Vol. 24, No. 12 ( 1990-12), p. 1195-1203
    Abstract: The ultimate goal of therapeutic intervention in a critically ill patient is to maintain oxygen homeostasis where delivery of oxygen to the cells is greater than, or at least equal to, the oxygen demand of the cells. Oxygen demand varies from organ to organ. Total body oxygen demand is the sum of all oxygen required by all tissues and organs for aerobic cellular function. Oxygen consumption (V̇O 2 ) is the quantity of oxygen actually used by the cells. V̇O 2 may be calculated if the values of cardiac output (CO), hemoglobin concentration, and arterial and venous oxygen saturations (SaO 2 and SV̄O 2 , respectively) are known. Under normal circumstances, the quantities of oxygen demanded and oxygen consumed are equal, but in situations of inadequate oxygen delivery, oxygen demand may not be satisfied and the quantity of oxygen actually consumed will be governed by the quantity delivered. This then may result in an oxygen deficit and, ultimately, cellular death. This article discusses the principles of oxygen homeostasis, techniques for measuring V̇O 2 , CO, and SV̄O 2 , and the relevance of these principles and techniques to clinical practice.
    Type of Medium: Online Resource
    ISSN: 1042-9611
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1990
    detail.hit.zdb_id: 2053518-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...